Last reviewed · How we verify
NCT05341804
Cognitive and Balance Dual Task Training for People With Schizophrenia
NA trial testing cognitive and balance dual task training in Schizophrenia in 84 participants. Completed in 15 September 2023.
15 September 2023
Quick facts
| Lead sponsor | Kaohsiung Medical University Chung-Ho Memorial Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 84 |
| Start date | 10 May 2022 |
| Primary completion | 15 September 2023 |
| Estimated completion | 15 September 2023 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- cognitive and balance dual task training
- balance training
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
- Cognition — all drugs for Cognition →
- Balance — all drugs for Balance →
- Dual Task — all drugs for Dual Task →
Sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital
Who can join
Adults 40 to 75, any sex, with Schizophrenia or Cognition. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
After developing and pilot testing the training program, including the CogBals software, a 3-arm, single-blinded, randomized controlled trial is used to recruit 84 participants and then randomly allocated to the cognitive and balance dual task training group (COG\&BAL), the balance training group (BAL), and the treatment as usual group. The first two training groups (COG\&BAL, BAL) receive training for 60 minutes in a group format, 2 times weekly, for 12 weeks. All participants will be assessed at baseline and posttest. The primary outcome is balance function and secondary outcomes are cognitive functions and the muscular endurance of lower extremities.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05341804
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other Kaohsiung Medical University Chung-Ho Memorial Hospital trials
Trials by the same sponsor.
- NCT07342426 — High and Low Dose High-intensity Laser Therapy Lateral Epicondylitis · Phase 4 · recruiting
- NCT07346469 — Exploring the Effects of Magnesium Ions on Peripheral Neuropathy, Serum Magnesium Ion Concentration,Sleep Quality, and Q · NA · not yet recruiting
- NCT07154407 — AI-assisted Masticatory Muscle Training in Patients With Schizophrenia · NA · not yet recruiting
- NCT07154628 — Effect of Topical Lidocaine Spraying on the Vocal Cords Before Intubation During Robotic Surgery: a Randomized Controlle · Phase 4 · not yet recruiting
- NCT07126444 — Effects of an Exercise Snack Intervention on Employee Health and Work Performance · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05341804 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kaohsiung Medical University Chung-Ho Memorial Hospital
- Last refreshed: 21 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05341804.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing